ArticleJournal of molecular histology2025
FBXO10 inhibits ferroptosis and promotes the progression of esophageal squamous cell carcinoma by post-translational mediation of ACSL4 degradation.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Whole-body mass spectrometry imaging reveals metabolome and lipid peroxidation heterogeneity in zebrafish xenografts of esophageal squamous cell carcinoma.Analytical and bioanalytical chemistry · 2026Article
- Pharmaceutical therapies for pyroptosis in lung injury.Inflammopharmacology · 2026Review
- Crosstalk between protein lipidation and ubiquitination in tumor biology.Apoptosis : an international journal on programmed cell death · 2026Review
- Post-Translational Modification Networks in Ferroptosis: Orchestrating Defense, Drug Resistance, and Therapeutic Opportunities in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Review
- The Role of Mitochondrial DNA in Modulating Chemoresistance in Esophageal Cancer: Mechanistic Insights and Therapeutic Potential.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis, a regulated cell death mechanism characterized by iron dependency and lipid peroxidation, has been identified as a pivotal driver of tumor evolution and treatment resistance. Our findings reveal a previously unrecognized ubiquitination-driven mechanism in esophageal squamous cell carcinoma (ESCC), whereby F-box protein 10 (FBXO10) modulates ferroptosis susceptibility and oncogenic aggressiveness by orchestrating acyl-CoA synthetase long-chain family member 4 (ACSL4) degradation. Co-immunoprecipitation and immunofluorescence colocalization assays confirmed specific physical interaction between FBXO10 and ACSL4. Mechanistically, FBXO10 silencing stabilized ACSL4 by suppressing ubiquitination degradation, thereby potentiating ferroptosis through amplified lipid peroxidation and Fe
Indexed as
Identifiers
40616744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.